The sCD163/sTWEAK ratio in the peripheral blood mononuclear cells cultures correlates with disease severity in early systemic sclerosis
More details
Hide details
Department of Orthopedics and Traumatology, Medical University of Bialystok, Poland
Department of Allergology and Internal Medicine, Medical University of Bialystok, Poland
Center of Experimental Medicine, Medical University of Bialystok, Poland
Department of Medical Pathomorphology, Medical University of Bialystok, Poland
Department of Experimental Pharmacology, Medical University of Bialystok, Poland
Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Poland
Otylia Kowal-Bielecka   

Department of Rheumatology and Internal Medicine, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland. Tel.: +48 857 468 482; fax: +48 857 468 606.
Submission date: 2013-03-07
Acceptance date: 2013-05-28
Online publication date: 2013-05-31
Publication date: 2020-04-08
Pol. Ann. Med. 2013;20(2):95–99
CD163 is a scavenger receptor expressed exclusively on monocytes/macrophages and a decoy receptor for a TNF-related weak inducer of apoptosis (TWEAK), a multifunctional cytokine involved in the regulation of inflammatory response, angiogenesis and connective tissue remodeling. However, very little is known about the significance of CD163 and TWEAK interactions in vivo.

We hypothesized that CD163 and TWEAK interactions might play a role in the pathogenesis of systemic sclerosis (SSc).

Material and methods:
The concentrations of soluble CD163 (sCD163) and soluble TWEAK (sTWEAK) were measured by the enzyme immunoassays in the supernatants of cultured peripheral blood mononuclear cells (PBMC) from 25 patients with early SSc and 16 healthy controls (HC). The sCD163/sTWEAK ratio was calculated and its association with disease parameters was assessed.

Results and discussion:
The production of sTWEAK was comparable between SSc patients and HC (p > .05). The mean concentration of sCD163 and the mean sCD163/sTWEAK ratio were significantly greater in SSc patients as compared with HC (p < .05 for both). However, only sCD163/sTWEAK ratio, but not sCD163 or sTWEAK alone, correlated with the modified Rodnan skin score (Spearman R = 0.46) and, inversely, with forced vital capacity (R = −0.49) and diffusing capacity of the lungs for carbon monoxide (R = −0.50) in SSc patients.

We showed that there is an imbalance in the production of sCD163 and sTWEAK by the PBMC from SSc patients resulting in increased sCD163/sTWEAK ratio. Correlation of sCD163/sTWEAK ratio in PBMC supernatants with the severity of skin and lung involvement indicates that interaction of these two molecules might affect the development of SSc.

This study was supported by the research grants from the Medical University of Bialystok (Grant nos. 113-60783L and 123-60689).
None declared.
Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009;48(3):iii3–iii7.
Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn. 2012;122(1):18–23.
Bielecki M, Kowal K, Lapinska A, Chwiecko J, Skowronski J, Sierakowski S, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol. 2009;47(3):465–469.
Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis. Adv Med Sci. 2013;58(1):126–133.
Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007;178(12):8183–8194.
Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 2002;4(2):126–133.
Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol. 2003;23(4):594–600.
Frings W, Dreier J, Sorg C. Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester- activated T-lymphocytes, whereas membrane-bound protein has no effect. FEBS Lett. 2002;526(1–3):93–96.
Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/ macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128.
Juniantito V, Izawa T, Yuasa T, Ichikawa C, Yano R, Kuwamura M, et al. Immunophenotypical characterization of macrophages in rat bleomycin-induced scleroderma. Vet Pathol. 2013;50(1):76–85.
Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J. 2004;68(4):396–399.
Kowal K, Møller HJ, Dubuske LM, Moestrup SK, Bodzenta-Lukaszyk A. Differential expression of monocyte CD163 in single- and dual-asthmatic responders during allergen-induced bronchoconstriction. Clin Exp Allergy. 2006;36(12):1584–1591.
Kowal K, Silver R, Sławińska E, Bielecki M, Chyczewski L, Kowal-Bielecka O. CD163 and its role in inflammation. Folia Histochem Cytobiol. 2011;49(3):365–374.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr. TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205.
LeRoy EC, Medsger Jr. TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573–1576.
Macri SC, Bailey CC, de Oca NM, Silva NA, Rosene DL, Mansfield KG, et al. Immunophenotypic alterations in resident immune cells and myocardial fibrosis in the aging rhesus macaque (Macaca mulatta) heart. Toxicol Pathol. 2012;40(4):637–646.
Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, et al. Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol. 2002;130(1):156–161.
Matucci-Cerinic M, Allanore Y, Czirják L, Tyndall A, Müller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68(9):1377–1380.
Medsger Jr. TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255–273.
Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103–110.
Møller HJ. Soluble CD163. Scand J Clin Lab Invest. 2012;72(1):1–13.
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–737.
Mustonen E, Ruskoaho H, Rysä J. Thrombospondin-4, tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14: novel extracellular matrix modulating factors in cardiac remodelling. Ann Med. 2012;44(8):793–804.
Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, et al. Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol Int. 2012;32(2):403–407.
Shimizu K, Ogawa F, Yoshizaki A, Akiyama Y, Kuwatsuka Y, Okazaki S, et al. Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol. 2012;31(7):1059–1064.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581–590.
Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology. 2011;53(6):2003–2015.
Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7(5):411–425.
Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol. 2009;36(8):1657–1662.